Literature DB >> 16126006

Distinct profiles of Sjögren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF.

Peter Szodoray1, Philip Alex, Malin V Jonsson, Nicholas Knowlton, Igor Dozmorov, Britt Nakken, Nicolas Delaleu, Roland Jonsson, Michael Centola.   

Abstract

The formation of ectopic germinal centers (GC) has been described in Sjögren's syndrome (SS), although little is known about the molecular basis of this phenomenon. These structures are a focus of in situ autoantibody production and have been hypothesized to be involved in lymphomagenesis in SS patients. Serum cytokines also play an important role in SS pathogenesis in part via immune dysregulation and may therefore contribute to ectopic GC formation. Herein, highly multiplex cytokine screening of SS patients with (SSGC+) and without (SSGC-) GC formation was done to identify cytokine profiles that correlate with this phenomenon. Serum levels of B-cell activating factor (BAFF) were also screened as a potential biomarker of immune dysregulation in SS and SSGC formation. Univariate analysis demonstrated that serum levels of a broad spectrum of immune and inflammatory modulating cytokines are upregulated in SSGC+ and SSGC- patients relative to unaffected controls IL-1beta, IL-2, IL-6, IL-15, IFN-gamma and CCL4 (MIP-1beta). SSGC+ patients were distinguished from healthy individuals by higher levels of IL-4, IL-10, GM-CSF, IFN-alpha, CCL3 (MIP-1alpha), CCL11 (Eotaxin) and BAFF, while SSGC+ and SSGC- patients differed in CCL2 (MCP-1) expression. Discriminant function analysis (DFA), a multivariate discrimination method that uses observed differences to characterize groups when casual relationships are not well understood, was employed to identify a subset of these biomarkers that maximally discriminate among SSGC+, SSGC- and unaffected individuals. The biomarker having the strongest discriminatory power identified by DFA besides CCL11 (Eotaxin) and IFN-gamma was BAFF. The variables identified by DFA are interdependent and are often of mechanistic significance to the pathologic states they distinguish, suggesting that these factors modulate SS pathology and SSGC formation in a synergistic manner.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16126006     DOI: 10.1016/j.clim.2005.06.016

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  43 in total

1.  B-lymphocyte activating factor levels are increased in patients with Wegener's granulomatosis and inversely correlated with ANCA titer.

Authors:  Lucius Bader; Wenche Koldingsnes; Johannes Nossent
Journal:  Clin Rheumatol       Date:  2010-06-28       Impact factor: 2.980

2.  MiR-let-7d-3p regulates IL-17 expression through targeting AKT1/mTOR signaling in CD4+ T cells.

Authors:  Jian Wang; Xin Wang; Longfei Wang; Chao Sun; Changhao Xie; Zhijun Li
Journal:  In Vitro Cell Dev Biol Anim       Date:  2019-11-25       Impact factor: 2.416

Review 3.  [The dry eye. Current concepts on classification, diagnostics, and pathogenesis].

Authors:  C Jacobi; T Dietrich; C Cursiefen; F E Kruse
Journal:  Ophthalmologe       Date:  2006-01       Impact factor: 1.059

4.  Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept.

Authors:  Clio P Mavragani; Timothy B Niewold; Niki M Moutsopoulos; Stanley R Pillemer; Sharon M Wahl; Mary K Crow
Journal:  Arthritis Rheum       Date:  2007-12

Review 5.  T lymphocytes in Sjögren's syndrome: contributors to and regulators of pathophysiology.

Authors:  Gikas E Katsifis; Niki M Moutsopoulos; Sharon M Wahl
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

Review 6.  Oral Complications of Chronic Graft-Versus-Host Disease.

Authors:  Jane M Fall-Dickson; Steven Z Pavletic; Jacqueline W Mays; Mark M Schubert
Journal:  J Natl Cancer Inst Monogr       Date:  2019-08-01

7.  Clcn5 knockout mice exhibit novel immunomodulatory effects and are more susceptible to dextran sulfate sodium-induced colitis.

Authors:  Philip Alex; Mei Ye; Nicholas C Zachos; Jennifer Sipes; Thuan Nguyen; Maxim Suhodrev; Liberty Gonzales; Zubin Arora; Ting Zhang; Michael Centola; Sandra E Guggino; Xuhang Li
Journal:  J Immunol       Date:  2010-02-24       Impact factor: 5.422

8.  Current Aspects of Pathogenesis in Sjögren's Syndrome.

Authors:  Michael Voulgarelis; Athanasios G Tzioufas
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-12       Impact factor: 5.346

Review 9.  [Ophthalmological complications in Sjögren's syndrome].

Authors:  C Jacobi; C Cursiefen
Journal:  Z Rheumatol       Date:  2010-02       Impact factor: 1.372

Review 10.  Cytokines in Sjögren's syndrome.

Authors:  N Roescher; P P Tak; G G Illei
Journal:  Oral Dis       Date:  2009-06-10       Impact factor: 3.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.